NFKB1 and colitis: We presented substantial evidence demonstrating the capacity of GLP-1RAs to alleviate experimental colitis by inhibiting pro-inflammatory signalling pathways through the downregulation of the PI3K/AKT, NFκB, and CREB/PKA dependent signalling pathways.